Back

A k-mer based transcriptomics analysis for NPM1-mutated AML

Silva, R.; Riedel, C.; Guibert, B.; Ruffle, F.; Boureux, A.; Commes, T.

2023-02-02 genetic and genomic medicine
10.1101/2023.01.31.23285241 medRxiv
Show abstract

MotivationAcute Myeloid Leukemia is a highly heterogeneous disease. Although current classifications are well-known and widely adopted, many patients experience drug resistance and disease relapse. New biomarkers are needed to make classifications more reliable and propose personalized treatment. ResultsWe performed tests on a large scale in 3 AML cohorts, 1112 RNAseq samples. The accuracy to distinguish NPM1 mutant and non-mutant patients using machine learning models achieved more than 95% in three different scenarios. Using our approach, we found already described genes associated with NPM1 mutations and new genes to be investigated. Furthermore, we provide a new view to search for signatures/biomarkers and explore diagnosis/prognosis, at the k-mer level. AvailabilityCode available at https://github.com/railorena/npm1aml and https://osf.io/4s9tc/. The cohorts used in this article were authorized for use. Contact*therese.commes@inserm.fr

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.